Lee Chambers recognised as an 2025 inspirational D&I leader
Lee Chambers, the business psychologist and CEO of Male Allies UK, was nominated in a survey of 370 international diversity and inclusion professionals as an inspirational leader in the field of gender equality and male allyship. The list recognises who people in the profession see as thought leaders who are accelerating workplace inclusion across the globe.
Chambers features on this year list for the first time, and is joined by other practitioners whose focus on evidence based inclusion stands out in the current climate. This years list includes John Amaechi, Pamela Hutchinson and Zaheer Ahmad. The list, in it's 5th year, is one of the most prestigious pieces of recognition for those in the field of inclusion, given it solely selected by peers across the globe.
Diversity and Inclusion Leaders are a community of over 20,000 people, in roles relating to inclusion and those passionate about people and culture within organisations. They host a yearly summit and a range of expert led events across the calendar year, designed to upskill and equip leaders while fostering connection across industries.
On featuring on this years list, Lee Chambers said, "To be recognised and held up by those that work in the field is a moment to remember on my journey. Male Allies UK may only be a year old, but years of work have gone into ensuring we are impactful, relevant and innovative, and create outcomes that last for our clients. I wouldn't class myself as inspirational, but I do feel inspired by the difference we have made. This is my peers telling me to keep going, and I get fulfillment and energy from that."
This caps an excited first half of the year for the Male Allies UK team, and with the launch of their Voice of the Boys report in the House of Commons and collaborations with global companies across 12 sectors, they are just getting starting in making male allyship and gender equity a reality.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Smith & Nephew (SN) Receives a Hold from Stifel Nicolaus
Stifel Nicolaus analyst Dylan Van Haaften maintained a Hold rating on Smith & Nephew today and set a price target of £14.15. The company's shares closed today at p1,353.00. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Van Haaften covers the Healthcare sector, focusing on stocks such as Merck KGaA, Smith & Nephew, and Sartorius. According to TipRanks, Van Haaften has an average return of -5.5% and a 32.65% success rate on recommended stocks. In addition to Stifel Nicolaus, Smith & Nephew also received a Hold from Berenberg Bank's Sam England in a report issued on August 11. However, yesterday, Bank of America Securities reiterated a Buy rating on Smith & Nephew (LSE: SN). SN market cap is currently £11.76B and has a P/E ratio of 30.99. Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SN in relation to earlier this year.
Globe and Mail
3 hours ago
- Globe and Mail
AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 43% of AstraZeneca's total revenues) rose 18% in the second quarter of 2025, generating $6.3 billion in sales. In the first half of 2025, the Oncology segment generated almost $12 billion in revenues, which rose 16% year over year. The strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca also has a profit-sharing deal with Merck MRK for Lynparza. AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. A key new cancer drug approval was that of Truqap for HR-positive, HER2-negative (HR+ HER2-) breast cancer. The drug has seen a robust launch, recording sales of $302 million in the first half of 2025, driven by demand growth in the second-line biomarker-altered population. AstraZeneca expects further growth for Truqap to be driven by increased uptake within the PIK3CA population and additional global launches. AstraZeneca and partner Daiichi's drug, Datroway, was approved by the FDA for HR+ HER2- breast cancer in January and for EGFR-mutated non-small cell lung cancer (NSCLC) in June this year. Datroway witnessed encouraging early launch signals in the United States for the breast cancer indication in the first half, recording sales of $14 million. Important late-stage oncology candidates in AstraZeneca's pipeline are camizestrant (HR+ HER2- metastatic breast cancer), volrustomig (several types of cancers), sonesitatug vedotin (advanced or metastatic gastric or GEJ adenocarcinoma) and surovatamig (previously untreated follicular lymphoma). Regulatory applications seeking approval of Imfinzi for early-stage gastric and gastroesophageal junction cancers are under regulatory review. AstraZeneca expects continued growth of its oncology medicines in the second half, particularly Tagrisso, Enhertu, and Merck-partnered Lynparza and Imfinzi, despite the incremental impact of the Part D redesign. Our estimates for AstraZeneca's total oncology portfolio suggest a CAGR of around 11.1% over the next three years. Competition in the Oncology Space Other large players in the oncology space are Pfizer PFE, Merck and Bristol-Myers BMY. Pfizer boasts a strong portfolio of approved cancer medicines like Xtandi, Lorbrena, and the Braftovi-Mektovi combination. Pfizer's oncology revenues grew 9% in the first half of 2025. The addition of Seagen in 2023 also strengthened its position in oncology by adding four antibody-drug conjugates (ADCs) — Adcetris, Padcev, Tukysa and Tivdak. Pfizer also has a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, ADCs and immuno-oncology biologics. Merck's key oncology medicines are PD-L1inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Keytruda's sales rose 6.6% to $15.1 billion in the first half of 2025. Bristol-Myers' key cancer drug is PD-L1inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo's sales rose 9% to $4.82 billion in the first half of 2025. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
Globe and Mail
3 hours ago
- Globe and Mail
Poised for Explosive Growth: Is Your Portfolio Ready for This ETF?
Key Points Microsoft, Apple, Nvidia, and Broadcom are excellent businesses, but they all sport pricey valuations. The technology sector has historically backed up its premium valuation with exceptional earnings growth. A tech-focused ETF could be an effective tool for building a position around a handful of leading companies. 10 stocks we like better than Vanguard Information Technology ETF › After a slow start to the year, the tech sector is rocketing higher again -- driven by Nvidia and Microsoft becoming the first companies to surpass $4 trillion in market capitalization. There are many ways to invest in top tech stocks, such as buying them directly or going the route of an exchange-traded fund (ETF). If you scan the holdings of a low-cost growth-focused ETF, chances are it is anchored by tech stocks. Even the S&P 500 has a little over a third of its holdings in the tech sector. Investors looking for outsized exposure to hardware, software, and semiconductor giants may want to go with a low-cost technology sector ETF over a general growth ETF or S&P 500 index fund. Here's why the Vanguard Information Technology ETF (NYSEMKT: VGT) is worth a closer look, but may not be a good fit for your portfolio. Betting big on a handful of companies Roughly half of the ETF is invested in just four companies -- Nvidia, Microsoft, Apple, and Broadcom. Notable companies missing from the ETF include Alphabet and Meta Platforms, which are in the communications sector, and Amazon and Tesla, which are in the consumer discretionary sector. Microsoft is a major cloud computing player at the forefront of both consumer-facing and enterprise-level artificial intelligence (AI). Microsoft's high margins and accelerated growth rate help justify its expensive valuation. Apple has been criticized for falling behind the AI train. But the company isn't sitting idly by and doing nothing. Apple has been rolling out new tools and design upgrades for users. And Apple should arguably take a slow and purposeful approach to AI -- prioritizing user-friendly features rather than raw power. Nvidia's graphics processing units are the gold standard for AI data centers, while Broadcom is helping the major cloud computing companies design their own chips for specific applications. One major advantage for both companies is the quality of the customer base. Nvidia and Broadcom are both capitalizing on big spending from the top hyperscale customers. Over half of Nvidia's revenue in its latest quarter came from just four companies -- which are most likely Microsoft, Amazon, Alphabet, and Meta Platforms. On its second-quarter 2025 earnings call, Broadcom said that its latest Tomahawk 6 architecture flattens the AI cluster by packing more than 100,000 AI accelerators in two tiers instead of three. Combined with its networking portfolio, Broadcom expects three customers (likely the big cloud providers) to each deploy 1 million AI accelerator clusters in 2027, with a big portion of those deployments coming from custom XPUs. Buying the Vanguard Tech ETF instead of choosing one of these four stocks over the others gives investors exposure to cloud infrastructure, application software, gaming, electronics, consumer services, the high-performance and versatility of GPUs for data centers, custom AI chips, and more. And that's just from the top four holdings. There are 319 total holdings in the ETF. The technology sector has consistently justified its high valuation The Vanguard Tech ETF is a great way to get more exposure to Microsoft, Apple, Nvidia, and Broadcom than you'll find in an S&P 500 index fund or a Nasdaq -focused ETF. But there are some risks worth considering before diving in headfirst. The biggest one is valuation. The ETF sports a price-to-earnings ratio of 39.2 compared to 27.6 for the Vanguard S&P 500 ETF. Investors are willing to pay a premium for the tech sector compared to the S&P 500 because it is expected to grow earnings faster than the broader market. However, big tech companies must deliver on earnings expectations to justify the premium valuation. Historically, the tech sector has done a phenomenal job exceeding expectations, as it is by far the best-performing sector over the last decade. ^IXT data by YCharts Another reason to avoid the ETF is if you've reached your maximum desired exposure to some of its largest holdings. For example, if you already have a sizable position in a company like Nvidia and you aren't looking to add more, then buying the tech ETF isn't going to be a good fit. A high-octane ETF for investors who don't mind volatility When approaching any stock or ETF, it's best to align investment opportunities with your financial goals. There are plenty of reasons to believe that the tech sector can continue carrying the major indexes to new heights, but that doesn't automatically mean it's a good buy for all investors. The tech sector is expensive and doesn't offer a sizable amount of passive income. It can also be volatile. These downsides may outweigh the potential benefits of the sector for certain investors. However, if you have a high risk tolerance, a long-term investment time horizon, and don't mind the concentration in just a handful of stocks, then the Vanguard Information Technology ETF could be right up your alley. Should you invest $1,000 in Vanguard Information Technology ETF right now? Before you buy stock in Vanguard Information Technology ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vanguard Information Technology ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Daniel Foelber has positions in Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, Tesla, and Vanguard S&P 500 ETF. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
